Marin-Acevedo, J.A.; Withycombe, B.M.; Kim, Y.; Brohl, A.S.; Eroglu, Z.; Markowitz, J.; Tarhini, A.A.; Tsai, K.Y.; Khushalani, N.I.
Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers 2023, 15, 3180.
https://doi.org/10.3390/cancers15123180
AMA Style
Marin-Acevedo JA, Withycombe BM, Kim Y, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Tsai KY, Khushalani NI.
Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers. 2023; 15(12):3180.
https://doi.org/10.3390/cancers15123180
Chicago/Turabian Style
Marin-Acevedo, Julian A., Bethany M. Withycombe, Youngchul Kim, Andrew S. Brohl, Zeynep Eroglu, Joseph Markowitz, Ahmad A. Tarhini, Kenneth Y. Tsai, and Nikhil I. Khushalani.
2023. "Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma" Cancers 15, no. 12: 3180.
https://doi.org/10.3390/cancers15123180
APA Style
Marin-Acevedo, J. A., Withycombe, B. M., Kim, Y., Brohl, A. S., Eroglu, Z., Markowitz, J., Tarhini, A. A., Tsai, K. Y., & Khushalani, N. I.
(2023). Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers, 15(12), 3180.
https://doi.org/10.3390/cancers15123180
